

Title: Does higher BMI increase COVID-19 severity?: a systematic review and meta-analysis

**Akibul Islam Chowdhury¹, Md. Fazley Rabbi², Tanjina Rahman¹, Sompa Reza³,
Mohammad Rahanur Alam^{1*}**

Affiliations:

¹Department of Food Technology and Nutrition Science, Noakhali Science and Technology University, Bangladesh

²Department of Biotechnology and Genetic Engineering, Noakhali Science and Technology University, Bangladesh

³Institute of Nutrition and Food Science, University of Dhaka, Bangladesh

Corresponding Author:

Name: Mohammad Rahanur Alam

Address: Department of Food Technology and Nutrition Science,
Noakhali Science and Technology University, Noakhali-3814, Bangladesh

Phone numbers: +880 185 6688 190

E-mail address: rahanur.ftns@nstu.edu.bd

Funding: The authors received no specific funding for this study.

Acknowledgment: We would like to express our gratitude to the authors of the studies included in our study.

Statement of Competing Interests: The authors have declared no conflict of interest.

Ethics approval: Ethics approval was not required for this study

Submission declaration and verification: The Authors hereby consents to publish this research article. This article has not been published or submitted elsewhere for publication. The authors also declare that this work does not libel anyone, violate anyone's copyright, or common law rights.

Availability of data and material: The datasets generated during this study are available from the corresponding author on a reasonable request.

Authors' contribution: Mohammad Rahanur Alam and Akibul Islam Chowdhury has participated in the design of the study, data interpretation, and wrote the first draft of the manuscript., Md. Fazley Rabbi, Tanjina Rahman, and Sompa Reza helped in the literature review and study selection process. All authors read and approved the final manuscript.

Abstract:

Introduction: COVID-19 pandemic has caused havoc worldwide, and different comorbidities have been seen to exacerbate the condition. Obesity is one of the leading comorbidities, which is associated with many other diseases. In this paper, we present a systematic review and meta-analysis estimating the effects of overweight and obesity on COVID-19 disease severity.

Methodology: Two electronic databases (Medline and Cochrane library) and one grey literature database (Grey Literature Report) were searched using the following keywords: overweight, obesity, body mass index, respiratory disease, coronavirus, COVID-19. The risks of bias of the selected studies were assessed by using the Navigation Guide method for human data. Both random and fixed effect meta-analysis were determined using Review Manager (RevMan) software version 5.4.

Results: After initial screening, 12 studies (7 cohort studies, four case-control studies, and one cross-sectional study) were fulfilled the eligibility criteria, comprising a total of 405359 patients and included in the systematic review. The pooled risk of disease severity was 1.31 times higher based on both fixed and random effect model among those overweight patients, I^2 0% and 2.09 and 2.41 times higher based on fixed and random effect respectively among obese patients, I^2 42% compared to healthy individuals.

Conclusion: Overweight and obesity are common risk factors for disease severity of COVID-19 patients. However, further assessment of metabolic parameters included BMI, waist-hip ratio, and insulin levels, are required to estimate the risk factors of COVID-19 patients and understanding the mechanism between COVID-19 and body mass index.

Keywords: COVID-19; Overweight; Obesity; BMI

Introduction:

Coronavirus disease 2019 (COVID-2019)—caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus—was declared a pandemic by the World Health Organization on March 11, 2020 (1). As of December 1, 2020, COVID-19 has infected 61.8 million people worldwide, with a death toll of 1.4 million (2). Previously, two highly pathogenic Coronaviruses resulted in outbreaks of a severe acute respiratory syndrome (SARS) in 2003 in Guangdong province, China, and the Middle East respiratory syndrome (MERS) in Middle Eastern countries in 2012 (3-6). Multiple risk factors are associated with mortality in COVID-19 patients. An increasing body of data suggests that individuals with diabetes mellitus (7), hypertension, and severe obesity (BMI ≥ 40 kg/m²) are more likely to be infected and are at a higher risk for complications and death from COVID-19 (8-14). In China, it was found that patients with cardiovascular disease (10.5%) had the highest fatality rate than diabetes mellitus (7.3%), hypertension (6.0%), and cancer (5.6%) (15). Many countries mentioned body mass index (BMI) as a clinical risk factor of COVID-19, such as China (16), Italy (17), United States (9) as the immunity system plays a vital role in obesity-induced adipose tissue inflammation (11). Emerging literature suggests that adults with obesity under the age of 60 are more likely to be hospitalized (18). The prevalence of obesity among adults is increasing day by day due to insufficient physical activities. A previous study showed a strong correlation between obesity and complications of viral infections (influenza virus, SARS, and MERS) (19). Many studies found that excessive weight gain ≥ 18 kg may increase the risk of developing community-acquired pneumonia (7, 20). Severe obesity might increase the duration of hospital stay and the case fatality rate (14, 21). However, two earlier reports have suggested no difference in body mass index (BMI) between severe and non-severe groups (18, 22). Although several studies addressed the impact of the body mass index (BMI) on COVID-19, a definite conclusion has not been drawn yet. Hence, this meta-analysis was conducted to elucidate the relationship between obesity and COVID-19 by searching existing literature.

Methods:

Literature Search: We searched two electronic databases: MEDLINE (on October 20, 2020) and Cochrane library (on October 21, 2020). We also searched one grey literature database: Grey Literature Report (<http://greylit.org>) on October 21, 2020. Searches were performed using a search strategy in English. We searched the literature using the following keywords: overweight, obesity, body mass index, respiratory disease, coronavirus, COVID-19. Manual searching was also performed to identify potentially eligible studies.

Study selection: All articles found in the searches were downloaded, and duplicate articles were identified and excluded. Two independent authors screened the titles and abstracts for finding duplicates and then screened the full texts to select the eligible articles. If there were any disagreements between the review authors, a third author fixed the problems. Following the PRISMA guideline, the process of study selection is presented in a flow chart (Figure 1).




Figure 1: The flow chart of searching and selecting studies based on selected criteria for systematic review and meta-analysis.

Eligibility criteria: PECO definitions are described below:

- **Population:** We included all studies of people aged (≥ 15 years) and reported positive for the presence of coronavirus in their bodies by the RT-PCR technique. Studies that measured the body mass index (BMI) were included with standard procedure.
- **Exposures:** Studies that defined overweight and obesity with standard definition were included.
- **Comparators:** Healthy participants with optimum BMI were used as a comparator. All other comparators were excluded.
- **Outcomes:** Severity of disease was used as an outcome in this systematic review.

Types of study: We included studies that measured the effect of overweight and obesity on COVID-19 disease severity. Eligible studies were randomized control trials, cohort studies (both prospective and retrospective), and case-control studies. We also included observational study. Records published in English were included. Both published and unpublished studies were included. Studies conducted using unethical practices were excluded.

Types of effect measures: We included measures of the relative effect of overweight and obesity on the severity of disease (prevalence and incidence), compared with the patient with optimum BMI. We included relative effect measures such as RRs, ORs, and Hazard ratios. To facilitate meta-analysis, if a study presented an RR, then it was converted to OR. If a study presented estimates for effect from two or more alternative models that had been adjusted for different variables, then we systematically prioritized the estimate from the model that provided information on the relevant confounders or mediators, at least the core variables: age, sex, and socioeconomic position. We prioritized estimates from models adjusted for more potential confounders over those from models adjusted for fewer. For example, if a study presents estimates from a crude, unadjusted model (Model A), a model adjusted for one potential confounder (e.g., age; Model B) and a model adjusted for two potential confounders (e.g., age and sex; Model C), then we prioritized the estimate from Model C.

Data extraction: Two independent reviewers extracted the data on study characters (study authors, study country, population size, study year, exposure, and outcome), study design, and risk of bias (including source population representation, blinding, exposure assessment, outcome assessment, confounding, incomplete outcome data, selective outcome reporting, conflict of interest and other sources of bias).

Risk of bias assessment: There is no standard method of assessing the risk of bias of selected studies for doing systematic review. The risk of bias of this review was assessed by nine risk factors of bias included in the Navigation Guide method for human data. These were: (i) source population representation; (ii) blinding; (iii) exposure assessment; (iv) outcome assessment; (v) confounding; (vi) incomplete outcome data; (vii) selective outcome reporting; (viii) conflict of interest; and (23) other sources of bias. The ratings for all domains were: “low”; “unclear” and “high.” Two independent reviewers assessed the risk of bias of selected studies. Any disagreement was solved by the third reviewer. Funnel plots were generated to judge concerns on publication bias (Supplementary figures).

Statistical Analysis: We assessed heterogeneity by reporting the I^2 (% residual variation due to heterogeneity) and τ^2 (method of moments estimates of between-study variance) of the pooled estimate. Both random effect and fixed-effect models were used to measure the relationship between obesity and COVID-19 disease severity. The 95% confidence interval has been reported in a pooled analysis. All analysis was done by using Review Manager (RevMan) software version 5.4.

Result:

Study selection: A total of 193 individual studies were identified in our searches. Twelve studies fulfilled our eligibility criteria and were included in the systematic review (Figure 1).


Of the 12 included studies (24-35), nine studies were included in the meta-analysis (24, 26-30, 32, 34, 35).

Characteristics of included studies: Most of the studies were cohort studies (7 studies), followed by case-control studies (4 studies) and one cross-sectional analysis. The total population of the included studies was 405359. The most commonly studied countries were the United States (6 studies) and China (4 studies). The comparator of most studied was BMI $\leq 25\text{kg/m}^2$ (Table 1).

Nine studies reported the relation between COVID-19 disease severity with overweight and obesity (Table 3).

Risk of bias at individual study level: The risks of bias rating for each domain for all 12 studies for this outcome are presented in Table 2.

Measured outcome: The effect of overweight on disease severity of COVID-19 patients was measured comparing with normal body weight. The meta-analysis of selected nine studies showed that the pooled risk of disease severity was 1.31 times higher based on both fixed and



random effect model among those patients who were overweight, I² 0% (Figure 2 and 3).

Figure 2: Forest plot illustrating the Fixed effect model of the association between obesity and COVID-19 severity






Figure 3: Forest plot illustrating the Random effect model of the association between obesity and COVID-19 severity

The pooled risk of disease severity was 2.09 and 2.41 higher based on fixed and random effect respectively among obese patients compared with normal body weight patients, I^2 42%



(Figure 4 and 5).

Figure 4: Forest plot illustrating the Fixed effect model of the association between



overweight and COVID-19 severity

Figure 5: Forest plot illustrating the Random effect model of the association between overweight and COVID-19 severity

Table 1: Result of systematic review (published and grey article)

Source	Study design	Country	Population (n)	Median Age (IQR)	Sex	Used WHO interim guidance	Method of COVID-19 testing	Defined obesity	Other comorbidities measured	Findings	Definition of comparator
Eyal et al.	Retrospective cohort study	USA	572 were young, and 2,834 were old	NR	M/F	NR	Nasopharyngeal swab PCR test	BMI	Coronary artery disease (CAD), Congestive heart failure (CHF), Hypertension (HTN), Diabetes mellitus (1), cancer, hyperlipidemia	For both younger and old population who had a BMI above 40kg/m ² , was independently associated with mortality (p<0.001)	BMI<30
Mark et al	Cohort study	UK	387,109	NR	M/F	NR	RT-PCR	BMI	Diabetes, hypertension, cardiovascular disease	The relative risk ratio was higher among obese people with COVID-19 compared with a healthy weight.	BMI<25
Arthur et al	Retrospective study	France	124	60 (51-70)	M/F	Yes	Real-time reverse transcriptase–PCR	BMI	Diabetes, hypertension, dyslipidemia	Overweight and obesity were significantly more frequent among SARS-CoV-2 participants, and the requirement of IMV was significantly higher among obese and overweight participant	BMI<25
Ling et al	Retrospective	China	323	61	M/F	Yes	RT-PCR, CT	BMI	Smoking,	BMI showed no	BMI<25

	study								diabetes, critical disease designation, hypertension, WBC count, neutrophil count	significant effects on patients outcome (p>0.05)	
Markos et al	Retrospective cohort study	USA	103	60 (50-72)	M/F	NR	Reverse transcriptase–PCR assay	BMI	Hypertension, diabetes, heart disease	Admission to ICU and requirement of IMV were significantly associated with obesity and severe obesity	BMI<25
Temet et al	Case report	USA	167	72	M/F	NR	rRT-PCR	NR	Hypertension, cardiac disease, renal disease, diabetes mellitus, cancer, liver disease, pulmonary disease	Most of the facility residents had chronic health conditions with obesity	NR
Safiya et al	Case series	USA	5700	63 (52-75)	M/F	NR	Nasopharyngeal swab PCR test	BMI	Hypertension, diabetes, cancer, cardiovascular disease, liver disease, kidney disease, asthma	Obesity was identified as a common comorbidities	NR
Qingxian et al	Case series	China	383	NR	M/F	Yes	Real-time reverse transcription PCR method	BMI	Diabetes, hypertension, cardiovascular disease, liver disease, cancer	The risk of developing severe COVID-19 was 1.84 times and 3.40 times higher among overweight and obese patients, respectively,	BMI: 18.5-23.9

										especially in men.	
Kenneth et al	NR	China	214	NR	M/F	NR	Real-time reverse transcription PCR method	BMI	T2D, hypertension, dyslipidemia	The presence of obesity with metabolic associated fatty liver disease was significantly associated with the increased risk of severe COVID-19 disease	BMI<25
Qing et al	Retrospective study	China	112	65(49-78)	M/F	Yes	RT-PCR test	BMI	Hypertension, diabetes, coronary heart disease, atrial fibrillation	Body mass index was not significantly associated with the disease severity of COVID-19 patients	NR
Christopher et al (unpublished)	Cross-sectional study	USA	4103	52(36-65)	M/F	NR	Real-time RT-PCR	BMI	Diabetes, cancer, coronary kidney disease, coronary artery disease	BMI of the patients was significantly associated with hospitalization.	BMI:<30
Jennifer et al	Retrospective study	USA	3615	NR	M/F	NR	PCR	BMI	None	Higher BMI(\geq 30) and age<60 patients had high risk of admission in acute and critical care than lower BMI patients.	BMI<30

Did the study receive any support from a company, study author, or other entity having a financial interest in any of the exposures studied?	Low	Low	Low	Low	Low	Unclear	Low	Low	Low	Low	Low	Low
Did the study appear to have problems that could put it at risk of bias?	Low	Low	Low	Low	Low	Low	Low	Low	Low	Low	Low	Low
Total score (Extra 2 points for peer-reviewed article)	17	17	19	18	20	16	19	18	19	17	16	17

Table 3: Odds ratio of selective studies for meta-analysis

	Eyal et al	Arthur et al	Markos et al	Kenneth et al	Ling et al	Qingxian et al	Mark et al	Jennifer et al	Christopher et al
Overweight	1.1(0.5-2.3)	1.69(0.52-5.48)	2.27(0.59-8.83)	---	0.65(0.19-2.23)	1.74(1.03-2.93)	1.32(1.09-1.60)	1.1(0.8-1.7)	1.38(1.03-1.85)
Obese	5.1(2.3-11.1)	7.36(1.63-33.14)	5.39(1.13-25.64)	6.32(1.16-34.54)	2.86(0.79-10.31)	2.69(1.31-5.52)	1.97(1.61-2.42)	1.5(0.9-2.3)	1.73(1.03-2.90)

*Reference: Person with a normal BMI (18.5-24.9 wt/m²)

Discussion:

Of the 41 studies examined, some studies failed to find any association between BMI and COVID-19 (25, 27), and some studies did not measure BMI as a risk factor of COVID-19. The present study accumulated all the findings related to COVID-19 and BMI. Interestingly, it was found that BMI is a risk factor for COVID-19 patients. Overweight patients were 1.31 times higher at the risk of disease severity of COVID-19, and obese patients were 2.09 and 2.41 times higher susceptible to the severity of COVID-19 according to fixed and random effect model, respectively. Our study result is consistent with what has been found in previous reports (36-40). Different studies previously documented for different viral pathogens, including influenza, that obesity was a major risk factor for disease severity (41-43). During the 2009 H1N1 pandemic, it was found that the rates of hospitalization and deaths were higher among overweight and obese patients (7).

Several parameters with overweight and obesity play a role in disease severity of COVID-19. However, there is no exact mechanism that explains the contribution of overweight and obesity to severe COVID-19 outcomes. Nevertheless, it is said that obesity has adverse effects on lung function, diminishing forced expiratory volume and forced vital capacity (44). It is also reported that respiratory physiology is changed by obesity with the decreased functional capacity of the respiratory system (45). Another study found that obesity impaired immune system surveillance and response (46). Obesity was also found to impair the respiratory function, gas exchange, lung volume, increase comorbidities (CVD, T2D, kidney disease), and metabolic risk (hypertension, insulin resistance, and dyslipidemia), which contributed to disease severity of COVID-19 patients (47). Some studies explained why obese people presented a worse clinical outcome than a normal patient. These studies concluded that overweight and obese people have a different innate and adaptive immune response and have higher leptin and lower adiponectin concentrations, which leads to dysregulation of immune response and contributes to worsening pathogenesis conditions (48-50). Another study found that obesity reduced the activity of macrophages when an antigen is presented (51). Obesity was also directly associated with basal inflammatory status characterized by higher circulating Interleukin 6 and C-reactive protein levels (44). Obesity also impaired the adaptive immune system responses to the influenza virus (52). It is crucial to understand and find out the relationship between obesity and COVID-19 to reduce the risk of developing severe COVID-19 illness. The lifestyle of people should be improved to lessen risk both in the current and subsequent waves of COVID-19.

Conclusion:


Further assessment of metabolic parameters, including BMI, waist-hip ratio, and insulin levels, are required to estimate the risk factors of COVID-19 patients. Obesity is a common risk factor of numerous comorbidities that increase the severity of COVID-19 disease. So, we recommend that additional attention should be given to obese patients, along with other patients during this epidemic.


References:


1. Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). *International Journal of Surgery*. 2020.
2. Organization WH. Coronavirus disease 2019 (COVID-19): Weekly epidemiological update -1 December 2020. 2020.
3. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. *New England Journal of Medicine*. 2013;369(5):407-16.
4. Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt H-R, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *New England journal of medicine*. 2003;348(20):1967-76.
5. Zaki A. van BS, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med*. 2012;367(19):1814-20.
6. Zhong N, Zheng B, Li Y, Poon L, Xie Z, Chan K, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. *The Lancet*. 2003;362(9393):1353-8.
7. Morgan OW, Bramley A, Fowlkes A, Freedman DS, Taylor TH, Gargiullo P, et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A (H1N1) disease. *PloS one*. 2010;5(3):e9694.
8. (CDC) CfDcCaP. People who are at higher risk for severe illness 2020 [Available from: [simplehttps://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html)].
9. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region—case series. *New England Journal of Medicine*. 2020;382(21):2012-22.
10. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. *New England journal of medicine*. 2020;382(18):1708-20.
11. Kassir R. Risk of COVID-19 for patients with obesity. *Obesity Reviews*. 2020;21(6).
12. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *Jama*. 2020;323(18):1775-6.
13. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. *International journal of infectious diseases*. 2020.
14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The lancet*. 2020.
15. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *Jama*. 2020;323(13):1239-42.
16. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. *New England Journal of Medicine*. 2020.

17. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *Jama*. 2020;323(16):1574-81.
18. Zhang J-j, Dong X, Cao Y-y, Yuan Y-d, Yang Y-b, Yan Y-q, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020.
19. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. *American Journal of Physiology-Endocrinology and Metabolism*. 2020;318(5):E736-E41.
20. Louie JK, Acosta M, Samuel MC, Schechter R, Vugia DJ, Harriman K, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). *Clinical Infectious Diseases*. 2011;52(3):301-12.
21. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. *Critical Care*. 2020;24(1):1-3.
22. EL-Arabey AA, Abdalla M. Metformin and COVID-19: A novel deal of an Old Drug. *Journal of Medical Virology*. 2020.
23. Teixeira-Leite H, Manhães AC. Association between functional alterations of senescence and senility and disorders of gait and balance. *Clinics*. 2012;67(7):719-29.
24. Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. *Diabetes care*. 2020;43(7):1392-8.
25. Deng Q, Hu B, Zhang Y, Wang H, Zhou X, Hu W, et al. Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. *International journal of cardiology*. 2020.
26. Hamer M, Kivimäki M, Gale CR, Batty GD. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK. *Brain, Behavior, and Immunity*. 2020.
27. Hu L, Chen S, Fu Y, Gao Z, Long H, Wang J-m, et al. Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan, China. *Clinical infectious diseases*. 2020.
28. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al. Association of obesity with disease severity among patients with coronavirus disease 2019. *Obesity*. 2020;28(7):1200-4.
29. Klang E, Kassim G, Soffer S, Freeman R, Levin MA, Reich DL. Morbid Obesity as an Independent Risk Factor for COVID-19 Mortality in Hospitalized Patients Younger than 50. *Obesity*. 2020.
30. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. *Clinical Infectious Diseases*. 2020.
31. McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M, Schwartz NG, et al. Epidemiology of Covid-19 in a long-term care facility in King County, Washington. *New England Journal of Medicine*. 2020;382(21):2005-11.
32. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell LF, Chernyak Y, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. *MedRxiv*. 2020.
33. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *Jama*. 2020.
34. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. *Obesity*. 2020.
35. Zheng KI, Gao F, Wang X-B, Sun Q-F, Pan K-H, Wang T-Y, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. *Metabolism*. 2020;108:154244.
36. Du Y, Lv Y, Zha W, Zhou N, Hong X. Association of Body mass index (BMI) with Critical COVID-19 and in-hospital Mortality: a dose-response meta-analysis. *Metabolism*. 2020:154373.
37. Földi M, Farkas N, Kiss S, Zádori N, Vánca S, Szakó L, et al. Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis. *Obesity Reviews*. 2020;21(10):e13095.

38. Malik VS, Ravindra K, Attri SV, Bhadada SK, Singh M. Higher body mass index is an important risk factor in COVID-19 patients: a systematic review and meta-analysis. *Environmental Science and Pollution Research*. 2020;27(33):42115-23.
39. Pranata R, Lim MA, Yonas E, Vania R, Lukito AA, Siswanto BB, et al. Body mass index and outcome in patients with COVID-19: A dose–response meta-analysis. *Diabetes & metabolism*. 2020.
40. Yang J, Tian C, Chen Y, Zhu C, Chi H, Li J. Obesity aggravates COVID-19: an updated systematic review and meta-analysis. *Journal of medical virology*. 2020.
41. Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. *Clinical Infectious Diseases*. 2011;53(5):413-21.
42. Moser JAS, Galindo-Fraga A, Ortiz-Hernández AA, Gu W, Hunsberger S, Galán-Herrera JF, et al. Underweight, overweight, and obesity as independent risk factors for hospitalization in adults and children from influenza and other respiratory viruses. *Influenza and other respiratory viruses*. 2019;13(1):3-9.
43. Maccioni L, Weber S, Elgizouli M, Stoehlker A-S, Geist I, Peter H-H, et al. Obesity and risk of respiratory tract infections: results of an infection-diary based cohort study. *BMC public health*. 2018;18(1):271.
44. Sattar N, McInnes IB, McMurray JJ. Obesity a risk factor for severe COVID-19 infection: multiple potential mechanisms. *Circulation*. 2020.
45. Parameswaran K, Todd DC, Soth M. Altered respiratory physiology in obesity. *Canadian respiratory journal*. 2006;13.
46. Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. *International journal of obesity*. 2013;37(3):333-40.
47. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. *Nature Reviews Endocrinology*. 2020:1-2.
48. Andersen CJ, Murphy KE, Fernandez ML. Impact of obesity and metabolic syndrome on immunity. *Advances in Nutrition*. 2016;7(1):66-75.
49. Richard C, Wadowski M, Goruk S, Cameron L, Sharma AM, Field CJ. Individuals with obesity and type 2 diabetes have additional immune dysfunction compared with obese individuals who are metabolically healthy. *BMJ Open Diabetes Research and Care*. 2017;5(1).
50. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nature reviews immunology*. 2011;11(2):85-97.
51. Ahn S-Y, Sohn S-H, Lee S-Y, Park H-L, Park Y-W, Kim H, et al. The effect of lipopolysaccharide-induced obesity and its chronic inflammation on influenza virus-related pathology. *Environmental toxicology and pharmacology*. 2015;40(3):924-30.
52. Green WD, Beck MA. Obesity impairs the adaptive immune response to influenza virus. *Annals of the American Thoracic Society*. 2017;14(Supplement 5):S406-S9.








Odds Ratio

Odds Ratio

Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% CI
-------------------	-----------------	----	--------	--------------------

IV, Random, 95% CI

Arthur et al 2020	0.5247	0.6014	1.3%	1.69 [0.52, 5.49]
Christopher et al 2020	0.3221	0.1493	20.9%	1.38 [1.03, 1.85]
Eyal et al.2020	0.0953	0.4023	2.9%	1.10 [0.50, 2.42]
Jennifer et al 2020	0.0953	0.1625	17.6%	1.10 [0.80, 1.51]
Ling et al 2020	-0.4308	0.6275	1.2%	0.65 [0.19, 2.22]
Mark et al 2020	0.2776	0.0977	48.7%	1.32 [1.09, 1.60]
Markos et al 2020	0.8198	0.6875	1.0%	2.27 [0.59, 8.73]
Qingxian et al 2020	0.5539	0.2675	6.5%	1.74 [1.03, 2.94]



Total (95% CI)			100.0%	1.31 [1.14, 1.49]
-----------------------	--	--	---------------	--------------------------

Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 4.66$, $df = 7$ ($P = 0.70$); $I^2 = 0\%$

Test for overall effect: $Z = 3.93$ ($P < 0.0001$)

Identification

Records identified through
database searching
(n = 176)
MEDLINE (n=163)
Cochrane library (n=7)

Additional records identified
through other sources
(n = 17)

Screening

Records after duplicates removed
(n = 162)

Records screened
(n = 162)

Records excluded
(n = 121)

Eligibility

Full-text articles
assessed for eligibility
(n = 41)

Full-text articles
excluded, with reasons
(n = 29)
12 ineligible outcomes
13 ineligible exposures
4 ineligible study types
(review)

Included

Studies included in
qualitative synthesis
(n = 12)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 9)